Global News

Healthrageous, United BioSource, Boehringer Ingelheim launch SMART digital diabetes study

Friday, July 19, 2013 01:30 PM

Healthrageous, a digital health management company, and pharmaceutical company Boehringer Ingelheim have launched the SMART study with United BioSource (UBC) to evaluate a digital technology enabled self-management solution to potentially improve the health status of people with type 2 diabetes. The goal of the solution is to leverage technology in a way that makes the personalized journey of self-managing diabetes easier for patients to self-manage their disease.

More... »

Alzheimer's Association articles call for global research collaboration

Friday, July 19, 2013 01:21 PM

A global, collaborative research effort based on public-private partnerships, similar to the projects in the 1950s and 1960s that successfully reduced polio worldwide, will advance the prevention, diagnosis and treatment of Alzheimer's disease, according to two articles written by leaders of the Alzheimer's Association and published in the July issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

More... »

IMI2 to launch in January 2014

Wednesday, July 17, 2013 01:07 PM

The European Innovative Medicines Initiative 2 (IMI2) is a Joint Technology Initiative (JTI) bringing together companies, universities, public laboratories, innovative SMEs, patient groups and regulators. It will pave the way for breakthrough vaccines, medicines and treatments to address Europe’s health challenges through a combined science and innovation effort.

More... »

Pathogenica, Illumina in co-marketing deal

Wednesday, July 17, 2013 12:30 PM

Pathogenica, a provider of medical diagnostic sequencing services and products, and Illumina have agreed to co-market in the Asia Pacific region a new version of Pathogenica's HAI BioDetection kit compatible with Illumina's MiSeq benchtop sequencing system. The combined solution will enable users to identify an expanded panel of bacteria and drug resistance genes present within clinical specimens and mixed cultures or isolates.

More... »

Sorrento, BGN Technologies collaborate on Hepatitis C

Wednesday, July 17, 2013 12:17 PM

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, and BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, have entered into an option and license agreement covering several anti-Hepatitis C Virus (HCV) antibody clones identified from patients who have recovered from HCV infections. Sorrento plans to develop these early findings into a potential therapeutic product.

More... »

Boston-based Alzheimer's disease research highlighted at Alzheimer's Association International Conference 2013

Tuesday, July 16, 2013 09:35 AM

Three studies reported at the Alzheimer's Association International Conference 2013 (AAIC) demonstrate the vitality and diversity of Alzheimer's disease research being conducted in Boston, the host city for this year's conference.

More... »

Ipsen, Harvard Medical School to collaborate

Monday, July 15, 2013 10:50 AM

Global pharmaceutical company Ipsen has initiated an R&D collaboration on novel engineered botulinum toxins with Harvard Medical School. Ipsen will fund Harvard research for at least three years to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of neurologic diseases.

More... »

Ipsen acquires Syntaxin

Monday, July 15, 2013 10:48 AM

Global pharmaceutical company Ipsen has acquired Syntaxin, a U.K.-based private life sciences company specialized in botulinum toxin engineering. Ipsen will pay $36.4 million up front, as well as up to $169 million in development and commercial milestones.

More... »

Artes Biotechnology, Bio Farma collaborate on vaccines

Monday, July 15, 2013 10:46 AM

Germany-based biotech Artes and Bio Farma, based in Indonesia, have joined to develop and manufacture vaccine candidates. The collaboration involves Artes’ specialization in cell line and process development, VLP-based vaccines and technology transfer for production processes, and Bio Farma’s experience manufacturing vaccines for the Indonesian domestic and international markets.

More... »

Mitsubishi Tanabe Pharma acquires Medicago in $357 million deal

Friday, July 12, 2013 03:13 PM

Mitsubishi Tanabe Pharma (MTPC) has agreed to acquire Quebec-based Medicago, a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs).

More... »